MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Identification and analysis of differential miRNA in exosomes of dopaminergic neurons overexpressing α-synuclein

    Y. Liang, D. Lin, T. Zhou, D. Zheng (Guangzhou, China)

  • Identification of Comprehensive PD Subtypes Using PPMI Study Data with Recurrent Neural Networks

    X. Zhang, Y. Zhao, H. Sarva, C. Henchcliffe, F. Wang (New York, NY, USA)

  • Identification of gut microbial genes in Parkinson’s disease by shotgun metagenomic analysis

    Y. Qian, X. Yang, S. Xu, S. Chen, Q. Xiao (Shanghai, China)

  • Identification of L-DOPA “on/off” states using speech-based analysis in Parkinson’s disease subjects

    R. Norel, C. Agurto, S. Heisig, R. Ostrand, B. Ho, V. Ramos, H. Zhang, K. Erb, J. Rice, G. Cecchi (Yorktown Heights, NY, USA)

  • Identification of modifiers of the age of onset variance and disease progression in a Dutch cohort of Machado-Joseph disease patients

    M. Huang, V. Leotti, J. Vries, G. Meerman, E. Brunt, C. Bemelmans, H. Kampinga, L. Jardim, D. Verbeek (Groningen, Netherlands)

  • Identification of putative serum biomarkers for parkin-related Parkinson’s disease by metabolome analysis

    T. Ogawa, T. Hatano, A. Okuzumi, S. Ueno, A. Mori, Y. Oji, M. Fujimaki, T. Koinuma, S. Saiki, N. Hattori (Tokyo, Japan)

  • Identifying delirium and it prevalence in idiopathic Parkinson’s disease

    R. Lawson, C. McDonald, D. Burn (Newcastle upon Tyne, United Kingdom)

  • Identifying the neural correlates of doorway freezing in Parkinson’s disease

    E. Matar, J. Shine, P. Ward, M. Gilat, K. Ehgoetz-Martens, M. Frank, A. Moustafa, S. Naismith, S. Lewis (Sydney, Australia)

  • Identifying therapeutic targets from spontaneous beneficial brain lesions

    J. Joutsa, L. Shih, A. Horn, M. Reich, J. Hsu, O. Wu, N. Rost, M. Fox (Charlestown, MA, USA)

  • Imaging Analysis of the International Tourette Syndrome Deep Brain Stimulation Registry and Database

    K. Johnson, D. Servello, M. Porta, A. Bona, J. Ostrem, E. Bardinet, ML. Welter, A. Lozano, J.C. Baldermann, J. Kuhn, D. Huys, T. Foltynie, M. Hariz, E. Joyce, L. Zrinzo, Z. Kefalopoulou, JG. Zhang, FG. Meng, C. Zhang, Z. Ling, A. Smeets, L. Ackermans, V. Visser-Vandewalle, A. Mogilner, M. Pourfar, W. Hu, A. Gunduz, K. Foote, M. Okun, C. Butson (Salt Lake City, UT, USA)

  • Imaging neurodegeneration biomarkers in Essential Tremor

    S. Pietracupa, M. Bologna, G. Pasqua, S. Tommasin, N. Petsas, F. Elifani, A. Berardelli, P. Pantano (Pozzilli, Italy)

  • Immediate Effect of Elastic Taping on Balance and Postural Control in Early Parkinson’s Disease: A Pilot Study

    E. Göz, B. Balci, B. Dönmez, Çolakoğlu, R. Çakmur (Izmir, Turkey)

  • Immediate effects of walking training with Honda Walking Assist Device on gait parameters of Parkinson’s disease

    R. Matsugaki, K. Nawata, H. Kako, J. Shiraishi, S. Saeki (Kitakyushu-shi, Japan)

  • Immunological causes of atypical parkinsonism

    M. Cesarini, J. Etcheverry, G. Da Prat, G. Rojas, N. Gonzalez Rojas, E. Gatto (La Plata, Argentina)

  • Impact of a Parkinson’s Disease-Specific Order Set on Inpatient Medication Administration

    D. Larson, C. Zadikoff, M. Afshari, Y. Kianirad (Chicago, IL, USA)

  • Impact of Age on Levodopa dosage regimes in Idiopathic Parkinson’s Disease

    L. Scourfield, S. Sultana, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

  • Impact of changes in resistance on current delivered in constant voltage DBS stimulator in Parkinson’s Disease

    S. Meka, T. Syed, S. Kumar, S. Tandra, R. Kandadai, S. Turaga, R. Borgohain (Hyderabad, India)

  • Impact of Disease Duration and Anatomical Target on Health Related QoL in Patients Receiving DBS: Results from the Product Surveillance Registry

    M. Schiess, S. Falowski, S. Palfi, J. Azulay, A. Lopez-Rios, L. Defebvre, J. Espinoza, K. Sandberg, B. Van Dorn, T. Weaver, P. Konrad, J. Krauss (Houston, TX, USA)

  • Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials

    R. Pahwa, S. Isaacson, J. Jimenez-Shahed, I. Malaty, A. Deik, R. Gandhy, R. Johnson, R. Patni (Kansas City, KS, USA)

  • Impact of electrode impedance changes in clinical outcomes of patients with Parkinson’s disease and subthalamic nucleus deep brain stimulation

    ME. Contreras Pinto, J. Martins, C. Cerquera, S. Dias, D. Giraldo Salazar, JS. Saavedra Moreno, F. Vallderiola Serra (La Serena, Chile)

  • Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea

    F. Pagan, W. Jost, A. Friedman, O. Michel, C. Oehlwein, J. Slawek, A. Bogucki, S. Ochudlo, M. Banach, B. Flatau-Baqué, J. Csikós, A. Blitzer (Washington, DC, USA)

  • Impact of Late-onset REM Sleep Behavior Disorder on the Symptoms of Parkinson’s Disease

    Y. Saitoh, M. Murata, Y. Takahashi (Tokyo, Japan)

  • Impact of postural stability estimation in HY scale. (Pull test Vs. limits of stability assessment)

    P. Serrano, A. Arroyo, J. Andreo, V. Cortés, JP. Romero (Madrid, Spain)

  • Impact of STN-DBS on Medication Reduction

    M. Carmona-Abellán, G. de Ulibarri, J. Guridi, P. Clavero, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

  • Impact of Subthalamic Nucleus Stimulation on Striatal Dopamine Transporter in Parkinsonian Rat Models

    W. Xian, Q. Guo, L. Jiang, Z. Pei, L. Chen (Guangzhou, China)

  • Impact of SYN120 (a Dual 5-HT6/5-HT2A antagonist) on psychiatric symptoms in patients with Parkinson’s disease dementia: Results from a Phase 2a Study

    D. Weintraub (Philadelphia, PA, USA)

  • Impact on the Quality of Life (CV) of people with Parkinson’s disease participating in community workshops of the public health system of Coquimbo, Chile

    S. Stange, D. Mansilla, Y. Diaz, Y. Córdoba (Coquimbo, Chile)

  • Impaired performance on measures of goal-directed behavior are associated with greater caregiver burden in Parkinson’s disease

    N. Dahodwala, C. McMillan, C. Nwadiogbu, J. Liu, A. Miller, M. Pavon, D. Weintraub, L. Massimo (Philadelphia, PA, USA)

  • Impaired reaching movements in idiopathic cervical dystonia patients

    A. Castagna, L. Sciumè, A. Caronni, D. Anastasi, A. Montesano, A. Marzegan (Milano, Italy)

  • Impaired stopping reversed through dopamine replacement in Parkinson’s disease

    S. Choudhury, A. Roy, R. Singh, K. Chatterjee, B. Mondal, M. Baker, S. Baker, H. (Kolkata, India)

  • Impaired topographic organization in cognitively unimpaired drug-naïve patients with rigidity-dominant Parkinson’s disease

    Y.B. Hou, Q.Q. Wei, R.W. Ou, J. Yang, W. Song, Q.Y. Gong, H.F. Shang (Chengdu, People’s Republic of China)

  • Improved sleep structure after cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus

    N. Nishida, T. Murakami, Y. Watanabe, H. Toda, S. Matsumoto, K. Iwasaki (Osaka, Japan)

  • Improvement in chorea and function in a patient with dystonia-choreoathetosis cerebral palsy after treatment with bilateral pallidal deep brain stimulation

    Y. Fernandez, B. Kopell, W. Tse (New York, NY, USA)

  • Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

    C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

  • Improvement of antisaccade amplitude by the STN DBS and target eccentricity

    A. Yugeta, Y. Terao, Y. Ugawa (Tokyo, Japan)

  • Improvement of Levodopa-Responsive Chronic Pain after STN-DBS in Parkinson’s disease

    A. Gera, G. Pal (Chicago, IL, USA)

  • Improvements of tremor control and life quality of refractory essential tremor patients after MR-guided focused ultrasound thalamotomy – A Taiwan experience

    H.C. Lai, K. Tsai, W.C. Chang, T. Taira, C.Y. Wei (Changhua County, Taiwan)

  • Improving clinical data collection at patients’ home in Parkinson’s disease: The Sleep Fit app

    A. Mascheroni, C. Ferlito, S. Hackethal, S. Caverzasio, E-K. Choe, Y. Luo, F. Faraci, A. Kaelin-Lang, A. Puiatti, P-L. Ratti, M. Marazza (Manno, Switzerland)

  • Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)

    M. Alsahab, S. Pradhan, A. Chatterjee (Reading, United Kingdom)

  • Impulse control disorders and compulsive behaviours in Parkinson’s disease. Results from the COPPADIS Study Cohort

    S. Jesus Maestre, M. Labrador Espinosa, A. Adarmes Gómez, C. Mendez Barrio, JC. Martinez Castrillo, A. Alonso Cánovas, P. Sanchez Alonso, S. Novo Ponte, MG. Alonso Losada, N. Lopez Ariztegui, J. Segundo Rodriguez, MI. Morales Casado, I. Gaston, F. Lacruz Bescos, P. Clavero Ibarra, J. Kulisevsky, J. Pagonabarraga Mora, B. Pascual Sedano, P. Martinez Martín, D. Santos Garcia, P. Mir Rivera, G. Coppadis Study (Seville, Spain)

  • Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion

    K. Kashihara, M. Kitayama (Okayama, Japan)

  • Impulsive-Compulsive Behaviour disorders: A longitudinal study in de-novo in Parkinson’s disease patients

    L. Ricciardi, C. Lambert, M. Edwards, F. Morgante (London, United Kingdom)

  • In vivo MRI signatures of hippocampal subfield pathology in patients with Parkinson’s disease and psychosis

    A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Hegde, A. Shyam Sundar, R. Yadav, P. Pal (Bangalore, India)

  • In vivo staging of pathology in REM sleep behaviour disorder

    K. Knudsen, T. Fedorova, A. Hansen, M. Sommerauer, M. Otto, K. Svendsen, A. Nahimi, M. Stokholm, N. Pavese, C. Beier, D. Brooks, P. Borghammer (Aarhus, Denmark)

  • Incidence of Parkinson’s disease: Pooled analysis of six high-quality incidence studies with long-term follow-up

    A. Macleod, M. Camacho, J. Evans, C. Williams-Gray, R. Lawson, L. Forsgren, G. Alves, O.B. Tysnes, C. Counsell (Aberdeen, United Kingdom)

  • Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study

    C. Borrue-Fernandez, J. Fernandez- Cuesta, MJ. Abenza Abildua (San Sebastian Reyes, Spain)

  • Incobotulinum toxin type A for the treatment of biceps/triceps co-contraction due to obstetrical brachial plexus lesion

    G. Ianieri, R. Marvulli, G. Gallo (Bari, Italy)

  • Increased Parkin expression in a PARK20 (SYNJ1 mutation) iPSCs-based model

    W. Mandemakers, R. Masius, E. Berger, M. Grochowska, M. Quadri, M. Minneboo, M. Picillo, P. Barone, J. Schwamborn, V. Bonifati (Rotterdam, Netherlands)

  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series

    C. Wang, E. Wang, H. Lei (Tucson, AZ, USA)

  • Incremental hourly burden of “OFF” episodes on patient quality of life and health resource use among patients with Parkinson’s disease: A Neurologist/Patient Real World Assessment in the US

    K. Rajagopalan, J. Barton, J. Pike (Marlborough, MA, USA)

  • Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

    D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

  • Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

    P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

  • Influence of disease progression on the quality of life of individuals with spinocerebellar ataxia type 10

    L. Santos, M. Zonta, H. Teive, N. Mello, F. Neto, A. Macedo (Curitiba, Brazil)

  • Influence of dopamine deficiency on interhemispheric crosstalk in Parkinson’s disease

    P. Loehrer, F. Nettersheim, I. Weber, F. Jung, L. Timmermann (Marburg, Germany)

  • Influence of Wearing Empty Backpack on Gait and Balance in Patients with Degenerative Parkinsonian syndrome

    S. Lee, D. Heo, J. Park (Bucheon, Republic of Korea)

  • Inherited neuromyotonia associated with a dominant-negative KCNQ2 mutation

    Y.T. Hsu, W.D. Lin, Y.W. Yang, D.C. Wu, C.H. Tsai (Taichung, Taiwan)

  • Inhibition of HDAC4 attenuates rotenone-induced abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y cells

    L. Wang, L. Liu, T. Wang (Wuhan, China)

  • Inpatient care for Parkinson’s disease in Germany: Analysis of more than one million cases from the years 2010 to 2015

    L. Tönges, D. Bartig, S. Muhlack, W. Jost, R. Gold, C. Krogias (Bochum, Germany)

  • Instrumental assessment of upper extremity bradykinesia in UPDRS testing based on depth video data

    K. Otte, L. Rasche, H. Röhling, B. Kayser, S. Mansow-Model, F. Paul, A. Brandt, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

  • Instrumented gait analysis identifies potential predictors for Parkinson’s disease converters

    S. Del Din, M. Elshehabi, B. Galna, C. Hansen, M. Hobert, U. Suenkel, D. Berg, L. Rochester, W. Maetzler (Newcastle upon Tyne, United Kingdom)

  • Insular atrophy as a marker of depression in Multiple System Atrophy: A voxel-based morphometry study

    N. del Campo, N. Wolpe, O. Phillips, C. Arbus, F. Ory-Magne, M. Galitzky, C. Thalamas, C. Brefel-Courbon, A. Pavy-LeTraon, P. Péran, O. Rascol (Toulouse, France)

  • Insulin degrading enzyme, a novel key protein against alpha-synuclein oligomers formation?

    I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

  • Integrated Complimentary Yoga and Ayurveda Treatment Confers Significant Benefits in PD Patients

    H. Babu, U. Kumbhare, T. Raju, N. R, N. R (Bengaluru, India)

  • Integrated whole exome sequencing and chromosomal microarray in familial Parkinson’s disease

    L. Robak, R. Du, B. Yuan, S. Gu, Z. Akdemir, J. Jankovic, J. Lupski, J. Shulman (Houston, TX, USA)

  • Intellectual disability with spastic ataxia: Atypical Infantile neuroaxonal dystrophy with absent spheroids

    A. Elavarasi, V. Goyal, P. Samal (Puducherry, India)

  • Intensive speech rehabilitation in degenerative ataxias improves intelligility

    A. Vogel, N. Rommel, M. Synofzik (Melbourne, Australia)

  • Interaction between MAPT H1 and APOE4 in early Parkinson’s Disease

    C. Lambert, Z. Ahmed, P. Ostergaard, L. Ricciardi, F. Morgante, T. Barrick, M. Edwards (London, United Kingdom)

  • Interaction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesiaInteraction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesia

    J.Y. Lin, Z.G. Liu, C.L. Xie, A.J. Yan (Shanghai, China)

  • Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synuclenopathies

    I. Martinez-Valbuena, R. Valenti-Azcarate, I. Amat-Villegas, M.M. Carmona-Abellan, I. Marcilla-Garcia, L. Alonso-Herrero, G. Marti-Andres, T. Tuñon-Alvarez, M.R. Luquin-Piudo (Pamplona, Spain)

  • Interaction of TDP-43 with IAPP in pancreatic beta cells of patients with sinucleinopathies

    R. Valenti-Azcarate, I. Martinez-Valbuena, C. Arean-Cuns, I. Marcilla-García, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

  • Intercultural differences in the frequency of impulsive control disorders in Parkinson’s disease

    J. Martinez Castrillo, C. Lastras Fernandez-Escandon, I. Domingez Zabaleta, C. Estevez Fraga, G. Sanchez Diez, A. Alonso Canovas (Madrid, Spain)

  • Interest in Genetic Testing in PD Patients with DBS

    A. Fraint, G. Pal, L. Verhagen, D. Hall, K. Marder (Chicago, IL, USA)

  • Internet of Things for Empowerment and Improved Treatment of Patients with Parkinson’s Disease

    L. Kani, M. Memedi, E. Kolkowska, G. Klein (Orebro, Sweden)

  • Interrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certification

    J. Winder, R. Roos, J.M. Burgunder, J. Marinus, R. Reilmann (Leiden, Netherlands)

  • Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease

    S. V G, P. Vavia (Mumbai, India)

  • Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

    S. Bhargava, V. Bhargava, A. Jain (Kanpur, India)

  • Intraoperative Electromyography can optimize pallidotomy for Parkinson’s disease and dystonias

    P. Brainer, A. Campos, A. Brainer, J. Brainer, P. Brainer, P. Coutinho, C. Lima, S. Laurentino, R. Bandin, M. Andrade (Recife, Brazil)

  • Intraoperative local field potential recordings from deep brain stimulation electrodes help predict efficacy of subthalamic nucleus stimulation in patients with Parkinson’s disease

    C. Chen, M. Liu, H. Chan, P. Tu, C. Lu, P. Brown (Taoyuan City, Taiwan)

  • Intraparenchymal Cyst Formation: A Rare Complication of Deep Brain Stimulation

    K. Tan, C. Zadikoff (Chicago, IL, USA)

  • Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

    M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

  • Intrathecal baclofen (ITB) therapy in the treatment of severe spasticity: Safety and Product Performance from a Large Multinational Multi-Center Registry

    M. Schiess, S. Eldabe, R. Spencer, K. Stromberg, T. Weaver, R. Plunkett (Houston, TX, USA)

  • INTREPID: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s disease

    J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

  • Intrinsic functional connectivity correlates of anxiety in cognitively unimpaired drug-naïve patients with Parkinson’s disease

    R. De Micco, M. Siciliano, F. Di Nardo, A. De Mase, A. Giordano, G. Caiazzo, F. Esposito, G. Tedeschi, A. Tessitore (Naples, Italy)

  • Intronic pentanucleotide TTTCA repeat insertion in SAMD12 gene causes familial cortical myoclonic tremor with epilepsy type 1

    Y. Chen, ZD. Cen, XS. Zheng, F. Xie, XD. Yang, XJ. Lu, ZY. Ouyang, HW. Wu, S. Chen, HM. Yin, X. Qiu, S. Wang, MP. Ding, YL. Tang, C. Jiao, CY. Liu, JF. Xiao, W. Luo (Hangzhou, China)

  • Investigating the clinical predictors of depression in Huntington’s disease: An Enroll-HD Database Study

    E. Furr Stimming, G. Colpo, N. Rocha, A. Teixeira (Houston, TX, USA)

  • Investigating the influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease

    YJ. Tan, Y. Zhao, ZH. Lu, S. Ng, E. Ng, F. Setiawan, WL. Au, EK. Tan, L. Tan, A. Ng (Singapore, Singapore)

  • Investigating the role of microRNA biogenesis pathway in neuroprotection in primary neuronal culture model of Parkinson’s disease

    J. Konovalova, S. Er, S. Soleimanbeigi, P. Chmielarz, A. Domanskyi (Helsinki, Finland)

  • Investigation of the incidences of non-motor symptoms in first-degree relatives and the spouses of patients with Parkinson’s disease

    J.B. Liu, X.J. Zhang, C.F. Liu (Yangzhou, China)

  • Investigation on the neural effects by differing the parameters of electrical stimulation for the relief of parkinsonian symptoms

    G.T. Kim, K.S. Kim, S.M. Lee (InCheon, Republic of Korea)

  • Is chronic ocular motor dysfunction in syndrome of antiGAD antibody reversible with immune therapy?

    A. Mook, S. Gunzler, G. Wilmot, A. Shaikh (Cleveland, OH, USA)

  • Is early onset ataxia phenotypically discernible from developmental disorders with impaired coordination?

    T. Lawerman, R. Brandsma, N. Maurits, O. Martinez-Manzanera, R. Lunsing, R. Brouwer, H. Kremer, D. Sival (Groningen, Netherlands)

  • Is Heart Rate variability a differential biomarker in REM sleep behavior disorder, Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy?

    F. Bernhard, G. Mayer, K. Kesper, A. Bauer, A. Janzen, E. Sittig, W. Cassel, D. Vadasz, N. Mix, V. Ries, W. Oertel (Marburg, Germany)

  • Is lowering stimulation frequency a feasible option to improve speech in Parkinson’s disease patients undergoing subthalamic deep brain stimulation?

    M. Fabbri, M. Zibetti, G. Ferrero, A. Accornero, I. Guimaraes, M. Rizzone, A. Romagnolo, J. Ferreira, L. Lopiano (Lisbon, Portugal)

  • Is primary writing tremor a form fruste of dystonia?

    A. Latorre, L. Rocchi, A. Berardelli, J. Rothwell, K. Bhatia (London, United Kingdom)

  • Is REM sleep behavior disorder associated with excessive daytime sleepiness in military veterans with Parkinson’s disease?

    A. Sarwar, S. Moore (Houston, TX, USA)

  • Is repetitive transcranial magnetic stimulation an effective tool to treat pain in Parkinson’s Disease?

    M. Bonello, T. Nurmikko, M. Steiger (Liverpool, United Kingdom)

  • Is safinamide useful for atypical Parkinsonian syndromes?

    M. Machío Castelló, M. Oses Lara, C. Feliz Feliz, J. del Val, P. García Ruiz (Madrid, Spain)

  • Is there a relationship between depression/anxiety and physical inactivity in Parkinson Disease?

    B. Aktar, B. Balci, B. Donmez Colakoglu (Izmir, Turkey)

  • Is there a role for miRNA in the diagnosis of PD?

    A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

  • It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

    M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

  • Item Response Theory Analysis of the Unified Dyskinesia Rating Scale Items

    C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley